Citizens Analyst Downgrades Cross Country Healthcare to Market Perform
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 07 2026
0mins
Should l Buy CCRN?
Citizens analyst Constantine Davides downgraded Cross Country Healthcare to Market Perform from Outperform after the company agreed to be acquired by Knox Lane for $13.25 per share.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CCRN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CCRN
Wall Street analysts forecast CCRN stock price to fall
8 Analyst Rating
1 Buy
7 Hold
0 Sell
Hold
Current: 13.130
Low
8.65
Averages
9.66
High
11.00
Current: 13.130
Low
8.65
Averages
9.66
High
11.00
About CCRN
Cross Country Healthcare, Inc. is a healthcare workforce solutions company delivering an AI-powered digital platform and advisory services. The Nurse and Allied Staffing segment provides traditional staffing, recruiting, and value-added total talent solutions, including temporary and permanent placement of travel and local nurse and allied professionals, and healthcare leaders within nursing, allied, physician, and human resources; vendor neutral programs and managed service programs; education healthcare services; caregiver services to PACE programs, and outsourcing services. The Physician Staffing segment provides physicians in many specialties, as well as certified registered nurse anesthetists, nurse practitioners, and physician assistants as independent contractors on temporary assignments throughout the United States at various healthcare facilities, such as acute and non-acute care facilities, medical group practices, government facilities, and managed care organizations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cross Country Partners with Optimé for Workforce Optimization
- Exclusive Partnership: Cross Country Healthcare has signed a 36-month exclusive agreement with Optimé to integrate advanced forecasting and optimization capabilities into its Intellify® platform, enhancing staffing precision and operational efficiency while reducing labor costs per service unit.
- Workforce Management Optimization: The introduction of Optimé enables Cross Country to better align workforce supply with patient demand, reduce manual decision-making time, and improve resource utilization, thereby strengthening its competitive position in the healthcare market.
- Integration Capabilities: The Optimé solution is designed to seamlessly integrate with major EHR, HR, payroll, and time-and-attendance systems, including Epic, Kronos, and Lawson, further enhancing Cross Country's workforce intelligence strategy by adding a more advanced optimization layer.
- Driving Intelligent Decision-Making: Executives at Cross Country emphasize that health systems require better decision-making and operational control, and the introduction of Optimé will make their platform more actionable and valuable, helping clients manage workforce complexity more intelligently.
See More
Monteverde Law Firm Investigates Cross Country Healthcare Sale
- Shareholder Recovery: Monteverde & Associates has successfully recovered millions for shareholders, showcasing its strength as a Top 50 firm in the 2025 ISS Securities Class Action Services Report, indicating its expertise and influence in shareholder rights protection.
- Transaction Investigation: The firm is investigating Cross Country Healthcare, Inc. (NASDAQ: CCRN) regarding its sale to KL Criss Cross Intermediate, LLC, where shareholders are expected to receive $13.25 per share in cash, raising questions about the fairness of this price in the market.
- Legal Service Transparency: Monteverde emphasizes that shareholders should inquire about a law firm's class action experience and historical success when selecting legal services, ensuring they receive professional legal support to protect their rights.
- Contact Information Provided: The firm offers free consultations, allowing shareholders to reach out to Juan Monteverde via email or phone for inquiries, demonstrating its commitment to customer service and shareholder rights advocacy.
See More
Investigation into Cross Country Healthcare Securities Violations
- Legal Investigation Launched: The Schall Law Firm has announced an investigation into Cross Country Healthcare, Inc. (NASDAQ: CCRN) for potential violations of securities laws, focusing on whether the company issued false or misleading statements that could undermine investor confidence.
- Investor Rights Protection: This investigation aims to safeguard investor rights and encourages shareholders who have suffered losses to participate, indicating a legal firm's commitment to corporate transparency and compliance, which may lead to potential legal liabilities for the company.
- Potential Impact Assessment: Should the investigation confirm any wrongdoing by the company, it could significantly negatively impact its stock price, thereby affecting investor trust and future financing capabilities.
- Legal Consultation Services: The Schall Law Firm offers free consultations to help investors understand their rights, demonstrating a commitment to protecting shareholder interests while potentially attracting more affected investors to participate in litigation.
See More
Middle East Peace Proposal Boosts Stock Futures
- Acquisition Surge: Cross Country Healthcare announced it will be acquired by Knox Lane in a $437 million all-cash deal, with shareholders receiving $13.25 per share, representing a ~31% premium to the prior close, and the transaction is expected to close in Q3 2026, marking the company's transition to private status and delisting from Nasdaq.
- Strong Earnings Drive Stock: Fortinet reported Q1 results that exceeded expectations with adjusted EPS of $0.82 and revenue rising 20% year-over-year to $1.85 billion, alongside an adjusted operating margin of 35.8%, while also raising its FY2026 revenue outlook to $7.71 billion to $7.87 billion, indicating robust market demand.
- Stock Price Decline Analysis: Despite Fastly's Q1 results beating expectations with nearly 20% year-over-year revenue growth, its stock plummeted 20% due to concerns over future growth sustainability and soft guidance, with Q2 revenue expected between $170 million and $176 million, reflecting market skepticism.
- Weak Ad Demand Impact: Snap's Q1 revenue grew 12% to $1.53 billion, in line with estimates, but its stock fell 10% due to weak demand from large North American advertisers and geopolitical uncertainties in the Middle East, with Q2 revenue expected between $1.52 billion and $1.55 billion, facing restructuring charges and market pressures.
See More
Cross Country Healthcare Acquired by Knox Lane in $437M Deal
- Acquisition Overview: Cross Country Healthcare announced its acquisition by Knox Lane in a $437 million all-cash deal, with shareholders receiving $13.25 per share, representing a ~31% premium over the last closing price and ~45% above the 90-day average price.
- Privatization Process: After the deal closes, Cross Country Healthcare will become a private company under Knox Lane and will be delisted from Nasdaq, marking a significant structural change that may impact its future capital operations.
- Brand Continuity: Despite the privatization, the company will continue to operate under its existing name and brand post-acquisition, indicating Knox Lane's emphasis on brand value and the intention to maintain customer trust and market recognition.
- Expected Timeline: The deal is anticipated to close in Q3 2026, pending approvals from shareholders and regulators, reflecting the importance of compliance and transparency in the acquisition process.
See More
Cross Country Healthcare to be Acquired by Knox Lane for $437 Million
- Acquisition Agreement: Cross Country Healthcare has entered into a definitive agreement with Knox Lane, which will acquire all outstanding shares at $13.25 per share in an all-cash transaction valued at $437 million, representing a 31% premium over the closing price on May 6, 2026.
- Positive Market Reaction: This transaction not only provides significant immediate value to shareholders but will also transition Cross Country Healthcare into a privately held company within Knox Lane's portfolio, with an expected closing in Q3 2026.
- Strategic Partnership Outlook: Knox Lane aims to leverage its expertise in the healthcare sector to assist Cross Country Healthcare in entering its next growth phase, further solidifying its leadership in healthcare workforce solutions.
- Technological Platform Advantage: Cross Country Healthcare's AI-driven digital platform, Intellify®, which is based on 40 years of industry experience, will continue to operate post-acquisition, enhancing the company's capabilities in optimizing labor ecosystems.
See More
Cross Country Partners with Optimé for Workforce Optimization
- Exclusive Partnership: Cross Country Healthcare has signed a 36-month exclusive agreement with Optimé to integrate advanced forecasting and optimization capabilities into its Intellify® platform, enhancing staffing precision and operational efficiency while reducing labor costs per service unit.
- Workforce Management Optimization: The introduction of Optimé enables Cross Country to better align workforce supply with patient demand, reduce manual decision-making time, and improve resource utilization, thereby strengthening its competitive position in the healthcare market.
- Integration Capabilities: The Optimé solution is designed to seamlessly integrate with major EHR, HR, payroll, and time-and-attendance systems, including Epic, Kronos, and Lawson, further enhancing Cross Country's workforce intelligence strategy by adding a more advanced optimization layer.
- Driving Intelligent Decision-Making: Executives at Cross Country emphasize that health systems require better decision-making and operational control, and the introduction of Optimé will make their platform more actionable and valuable, helping clients manage workforce complexity more intelligently.
See More
Monteverde Law Firm Investigates Cross Country Healthcare Sale
- Shareholder Recovery: Monteverde & Associates has successfully recovered millions for shareholders, showcasing its strength as a Top 50 firm in the 2025 ISS Securities Class Action Services Report, indicating its expertise and influence in shareholder rights protection.
- Transaction Investigation: The firm is investigating Cross Country Healthcare, Inc. (NASDAQ: CCRN) regarding its sale to KL Criss Cross Intermediate, LLC, where shareholders are expected to receive $13.25 per share in cash, raising questions about the fairness of this price in the market.
- Legal Service Transparency: Monteverde emphasizes that shareholders should inquire about a law firm's class action experience and historical success when selecting legal services, ensuring they receive professional legal support to protect their rights.
- Contact Information Provided: The firm offers free consultations, allowing shareholders to reach out to Juan Monteverde via email or phone for inquiries, demonstrating its commitment to customer service and shareholder rights advocacy.
See More
Investigation into Cross Country Healthcare Securities Violations
- Legal Investigation Launched: The Schall Law Firm has announced an investigation into Cross Country Healthcare, Inc. (NASDAQ: CCRN) for potential violations of securities laws, focusing on whether the company issued false or misleading statements that could undermine investor confidence.
- Investor Rights Protection: This investigation aims to safeguard investor rights and encourages shareholders who have suffered losses to participate, indicating a legal firm's commitment to corporate transparency and compliance, which may lead to potential legal liabilities for the company.
- Potential Impact Assessment: Should the investigation confirm any wrongdoing by the company, it could significantly negatively impact its stock price, thereby affecting investor trust and future financing capabilities.
- Legal Consultation Services: The Schall Law Firm offers free consultations to help investors understand their rights, demonstrating a commitment to protecting shareholder interests while potentially attracting more affected investors to participate in litigation.
See More
Middle East Peace Proposal Boosts Stock Futures
- Acquisition Surge: Cross Country Healthcare announced it will be acquired by Knox Lane in a $437 million all-cash deal, with shareholders receiving $13.25 per share, representing a ~31% premium to the prior close, and the transaction is expected to close in Q3 2026, marking the company's transition to private status and delisting from Nasdaq.
- Strong Earnings Drive Stock: Fortinet reported Q1 results that exceeded expectations with adjusted EPS of $0.82 and revenue rising 20% year-over-year to $1.85 billion, alongside an adjusted operating margin of 35.8%, while also raising its FY2026 revenue outlook to $7.71 billion to $7.87 billion, indicating robust market demand.
- Stock Price Decline Analysis: Despite Fastly's Q1 results beating expectations with nearly 20% year-over-year revenue growth, its stock plummeted 20% due to concerns over future growth sustainability and soft guidance, with Q2 revenue expected between $170 million and $176 million, reflecting market skepticism.
- Weak Ad Demand Impact: Snap's Q1 revenue grew 12% to $1.53 billion, in line with estimates, but its stock fell 10% due to weak demand from large North American advertisers and geopolitical uncertainties in the Middle East, with Q2 revenue expected between $1.52 billion and $1.55 billion, facing restructuring charges and market pressures.
See More
Cross Country Healthcare Acquired by Knox Lane in $437M Deal
- Acquisition Overview: Cross Country Healthcare announced its acquisition by Knox Lane in a $437 million all-cash deal, with shareholders receiving $13.25 per share, representing a ~31% premium over the last closing price and ~45% above the 90-day average price.
- Privatization Process: After the deal closes, Cross Country Healthcare will become a private company under Knox Lane and will be delisted from Nasdaq, marking a significant structural change that may impact its future capital operations.
- Brand Continuity: Despite the privatization, the company will continue to operate under its existing name and brand post-acquisition, indicating Knox Lane's emphasis on brand value and the intention to maintain customer trust and market recognition.
- Expected Timeline: The deal is anticipated to close in Q3 2026, pending approvals from shareholders and regulators, reflecting the importance of compliance and transparency in the acquisition process.
See More
Cross Country Healthcare to be Acquired by Knox Lane for $437 Million
- Acquisition Agreement: Cross Country Healthcare has entered into a definitive agreement with Knox Lane, which will acquire all outstanding shares at $13.25 per share in an all-cash transaction valued at $437 million, representing a 31% premium over the closing price on May 6, 2026.
- Positive Market Reaction: This transaction not only provides significant immediate value to shareholders but will also transition Cross Country Healthcare into a privately held company within Knox Lane's portfolio, with an expected closing in Q3 2026.
- Strategic Partnership Outlook: Knox Lane aims to leverage its expertise in the healthcare sector to assist Cross Country Healthcare in entering its next growth phase, further solidifying its leadership in healthcare workforce solutions.
- Technological Platform Advantage: Cross Country Healthcare's AI-driven digital platform, Intellify®, which is based on 40 years of industry experience, will continue to operate post-acquisition, enhancing the company's capabilities in optimizing labor ecosystems.
See More
